Develops briquilimab, an antibody therapy for mast cell-driven diseases, for patients with chronic urticaria and asthma.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic…View ↗
Our lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling…View ↗
We are focused on advancing Briquilimab in development as a chronic therapy in mast cell driven diseases such as CSU, CIndU, asthma and…View ↗
The company is developing therapies for patients with chronic spontaneous and inducible urticaria and asthma.
10-K for FY2025, filed Mar 30, 2026
10-Q for Q3 FY2026, filed Nov 16, 2026
$8MView ↗
8-K, filed Sep 28, 2026
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal…View ↗
8-K, filed Aug 14, 2026
On July 16, 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a former Cayman limited company that was engaged in…View ↗
A narrower therapeutic focus
The older report described development of therapies for mast and stem cell diseases, including transplant conditioning, blood disorders, and engineered stem cells. The latest report says stem-cell programs have been discontinued and the company is focused exclusively on mast cell-driven diseases.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company dedicated to enabling cures through therapeutics targeting mast and hemopoietic stem cells.…View ↗
Our drug development pipeline includes multiple product candidates designed to target mast and/or hematopoietic stem cells. Our lead…View ↗
Our lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (“SCF”) from binding to and signaling…View ↗
Competes with Celldex Therapeutics, Blueprint Medicines, Novartis, Sanofi Aventis, and Evommune
10-K for FY2025, filed Mar 30, 2026Celldex Therapeutics, Inc., which is developing an antibody to KIT that is being studied in mast cell diseases;View ↗
Loading...